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Intellectual Property
This section is devoted to giving readers an inside 
view of the crossing point between intellectual prop-
erty (IP) law and risk regulation. In addition to up-
dating readers on the latest developments in IP law 
and policies in technological ields (including chemi-
cals, pharmaceuticals, biotechnology, agriculture and 
foodstuffs), the section aims at verifying whether such 
laws and policies really stimulate scientiic and tech-
nical progress and are capable of minimising the risks 
posed by on-going industrial developments to individ-
uals’ health and safety, inter alia.
Medical Methods, Risks to Public 
Health and Exclusion from Patentability
Enrico Bonadio*
On 15 February 2010 the Enlarged Board of Appeal 
(EBA) of the European Patent Ofice (EPO) released 
an important decision regarding the exclusion from 
patentability of certain surgical methods (in the 
case G1/07).1 Under the European Patent Conven-
tion (EPC), methods of treatment by surgery are 
not patentable. Yet the exact scope of this exclusion 
has never been clear, as to date the EPO Technical 
Boards of Appeal seems to have reached different 
decisions on this matter.
The patent application examined by the refer-
ring board in G1/07 concerned magnetic resonance 
methods for imaging pulmonary and cardiac vas-
culature and assessing blood low using dissolved 
polarised 129Xe. In the context of these methods 
an embodiment relies on directly delivering such 
polarised 129Xe to an area of the heart through in-
jection, and these methods may be applied before 
either surgery or a drug therapy for the treatment of 
pulmonary and cardiac problems. During surgery 
they may provide useful real-time feedback in order 
to conirm success (e.g., surgically induced varia-
tions in blood perfusion).2 In the context of therapy 
they may permit the effect of the drug to be deter-
mined.
The EBA was then asked inter alia whether the 
above methods should be excluded from patent pro-
tection as a “method for treatment of the human or 
animal body by surgery” pursuant to the previous 
version of Article 52(4) of the European Patent Con-
vention (EPC), even if the above-described step – i.e. 
the injection of a contrast agent into the heart – does 
not per se aim at maintaining life and health.
In the latest version of EPC (EPC 2000) this exclu-
sion from patentability has been moved to Article 
53(c). The aim of this exception – which also covers 
therapeutic and diagnostic methods – is to eliminate 
obstacles to the freedom of practitioners to choose 
the best medical treatment to be applied to a patient, 
and to prevent any delay in the provision of such 
medical treatment. Indeed, this exclusion pursues a 
public interest, by aiming to prevent medical prac-
tice from being hindered by patent protection.
The EBA veriied whether the injection in ques-
tion can be considered as a “method for treatment 
of the human or animal body by surgery”. It did so 
even though in the context of the above methods 
the physical intervention on the body does not per 
se aim at maintaining life and health, but just serves 
the purpose of collecting data during an examina-
tion phase of a medical diagnosis. In other words, 
the question referred to the EBA was whether im-
aging methods comprising the described invasive 
step would fall under the surgery-related exception 
to patentability (now) contained in Article 53(c) EPC, 
even though such methods do not have curative pur-
poses or cause curative effects.
The ratio decidendi and conclusion of the EBA 
has been straightforward.
The EBA initially noted that the claimed methods 
involve physical interventions on the body which 
require professional medical skills to be carried out 
and involve substantial health risks, even when ex-
ecuted with the required medical professional care 
and expertise. The EBA held that the presence of 
such risk-related factors – e.g., harmful side effects 
or health risks for the subject – is material when 
verifying whether invasive surgical methods (as the 
one in G1/07) should be excluded from patentability, 
regardless of whether they have no curative purpos-
es or effects.
The EBA concluded that methods having purely 
or mainly non-therapeutic aims which include a 
substantial intervention on the body and do involve 
* Lecturer, University of Abertay Dundee, United Kingdom.
1 G 0001/07 Medi-Physics/Methods for imaging pulmonary and 
cardiac vasculature and evaluating blood low using dissolved 
polarized 129Xe. The decision can be downloaded at <http://
documents.epo.org/projects/babylon/eponet.nsf/0/cdd5fb0c315
3e9c3c12576cb00563d2d/$FILE/G1_07_en.pdf>.
2 The description of the application makes speciic references 
to the usefulness of the claimed methods during surgeries. For 
example, the methods in question may generate images which 
directly allow surgeons to decide on the course of action to be 
taken.
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health risks should be excluded from patentability 
under the surgery-related exception now contained 
in Article 53(c) EPC. The EBA also clariied that with 
reference to such risky inventions the rationale for 
the exception – i.e. to free doctors from being poten-
tially prevented by patents from applying the best 
possible treatment on their patients – clearly applies 
and justiies their exclusion from protection. In the 
decision the EBA took pains to give some examples 
of the above methods: i.e., (i) sex change operations, 
(ii) elimination of wrinkles, (iii) breast enhancement, 
(iv) embryo transfer, (v) organ transplantation, (vi) 
cosmetic surgery, (vii) sterilization and (viii) castra-
tion.
On the other hand, uncritical methods involv-
ing only a minor intervention and no substantial 
health risks (when carried out with the required care 
and skill) are to be considered patentable. Indeed, 
the EBA stressed that the progress and advance in 
safety and “the now routine character of certain, al-
beit invasive techniques, at least when performed on 
uncritical parts of the body, have entailed that many 
such techniques are nowadays generally carried out 
in a non-medical, commercial environment like in cos-
metic salons and in beauty parlours and it appears, 
hence, hardly still justiied to exclude such methods 
from patentability”.3 Examples of such uncritical 
methods could be (i) hair removal by optical radia-
tion, (ii) micro abrasion of the skin, (iii) piercing, (iv) 
tattooing, etc.
The lesson we can draw from this decision is that 
risk-related factors are paramount when it comes 
to deciding whether or not medical methods are 
to be excluded from patentability. These factors are 
amongst the socio-ethical and public health related 
considerations which must be taken into account 
when dealing with the inventions in question. This 
is therefore a relevant decision from EBA, which is 
the most important body in EPO. Indeed, it is com-
petent to take decisions only when the case law of 
lower boards – i.e., the Technical Boards of Appeal 
(TBA) – becomes inconsistent or when an important 
point of law arises, thus ensuring uniform applica-
tion of patent law across Europe.
In the past, the EPO has released decisions regard-
ing the patentability of medical methods in which it 
mentioned risk-related factors; such decisions, how-
ever, came from TBA.
For example, in 1994 the TBA clariied that a 
therapeutic method in which a laser was used in or-
der to modify a synthetic lenticule implanted on the 
cornea was deemed as not patentable, partly because 
it would be performed by or under the supervision 
of a medical practitioner due to the health risks con-
cerned. In particular, it was held that “the intention 
underlying [Article 52(4)] is to ensure that nobody who 
wants to use the methods speciied in this Article as 
part of the medical treatment of humans or animals, 
should be prevented from this by patents. Such medi-
cal treatments need not necessarily be carried out by 
physicians […]. However, where, in view of the health 
risks connected with such a treatment, a claimed 
method of treatment has to be performed by a phy-
sician or under his supervision, it will normally fall 
within the exclusion”.4
In 1997, a further decision was released con-
cerning a diagnostic method of Nuclear Magnetic 
Resonance (NMR) imaging including a step of in-
jecting contrast agents into the body. These agents 
were not devoid of any risk of side effects (e.g. head-
ache, malaise, fever, generalised lymphadenopathy, 
arthralgias, urticaria and even fatal anaphylactic 
shock), and so the method required the involvement 
of medical and technical staff. The Board therefore 
said that the above was a diagnostic method exclud-
ed from patentability pursuant to Article 52(4) EPC 
(now Article 53(c)).5
Furthermore, in 1999 it was held that those 
physical interventions on the human or animal 
body which – whatever their aim – are speciically 
designed to maintain the life or health of the body 
on which they are performed are to be considered 
methods for treatment by surgery within the mean-
ing of Article 52(4) EPC (now Article 51(a)). The 
Board clariied that this applies both to healing and 
to cosmetic surgery, and generally to all physical in-
terventions whose application is riskier and more 
complex, i.e., those interventions aimed at altering 
functions of the living body (e.g. castration to bring 
about changes in body functions linked to sex), as 
well as the removal of body parts (e.g., for transplan-
tation).6
3 G1/07 Medi-Physics/Methods for imaging pulmonary and car-
diac vasculature and evaluating blood low using dissolved polar-
ized 129Xe, p. 59.
4 T 24/91 Thompson/Cornea, OJ EPO 1995.
5 T 655/92 Nycomed/Contrast agent for imaging, OJ EPO 1998.
6 T 35/99 Georgetown University / Pericardial access, OJ EPO 
2000.
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The above decisions from TBA clearly took into 
consideration risk-related factors. 
However, it seems that in G1/07 the position taken 
by EBA is more straightforward, and attaches more 
importance to the risks stemming from the applica-
tion of the examined surgical method than ever be-
fore. Indeed, in this decision risk-related factors have 
been deliberately taken into account several times by 
the EBA, even in the inal order. This did not happen 
in the previous TBA rulings.
Moreover, the risks which are relevant in G1/07 
seem to be more objectively related to and stemming 
from the claimed method, and particularly its physi-
cal intervention on the body (without linking the 
risk factor with the involvement of practitioners). 
On the other hand, the previous cases heard by TBA 
linked the medical risk exclusively to the further is-
sue of whether a medical or technical staff should 
be responsible for carrying out said processes: i.e., 
a subjective requirement. In other terms, by stress-
ing that an invasive method involving a substantial 
health risk should be excluded from patentability 
without requiring the presence of medical staff7, the 
EBA made such a risk requirement more “objective” 
(as opposed to the previous TBA decisions).
Such a change in EPO case law is probably also 
due to a previous opinion released by EBA itself in 
G1/04 (concerning inter alia the proper interpreta-
tion of the terms “diagnostic methods”)8. In this 
opinion it was held inter alia that whether or not 
a diagnostic method should be excluded from pat-
entability may not depend on the participation of a 
medical or veterinary practitioner. This is because 
(i) it is dificult (if not impossible) to provide a dei-
nition of medical or veterinary practitioner in Eu-
rope within the framework of EPC and (ii) therefore 
for reasons of legal certainty the European patent 
grant procedure may not be rendered dependent on 
the involvement of such practitioners. This appears 
to be correct, as the exclusion at issue refers to the 
method, and not to the individual carrying out such 
method. Likewise, risk factors are related to medical 
methods as such, not to the further issue of whether 
medical or technical staff should participate and be 
responsible for carrying out these processes.
Pharmaceuticals
This section updates readers on the latest develop-
ments in pharmaceutical law, giving information on 
legislation and case law on various matters (such as 
clinical and pre-clinical trials, drug approval and mar-
keting authorisation, the role of regulatory agencies) 
and providing analysis on how and to what extent 
they might affect health and security of the individual 
as well as in industry.
End of the Transitional Period for 
Traditional Herbal Medicinal Products 
Coming Soon*
Tomasz Jablonski**
The transitional period for the application of the 
rules on traditional herbal medicinal products 
(THMP) is expiring on 30 April 2011. The approach-
ing end of the transitional period presents a timely 
opportunity to present some relections on the reg-
ulatory experience and the future perspectives of 
THMP.
A signiicant number of medicinal products, de-
spite their long tradition, do not fulil the require-
ments of a well-established medicinal use with rec-
ognised eficacy and an acceptable level of safety, nor 
are they eligible for a marketing authorisation. To 
maintain these products on the market, the Member 
States have enacted differing procedures and provi-
sions. The differences that currently exist between 
the provisions laid down in the Member States may 
hinder trade in traditional medicinal products with-
in European Union and lead to discrimination and 
distortion of competition between manufacturers of 
these products. They may also have an impact on 
the protection of public health, since the necessary 
guarantees of quality, safety and eficacy could be 
impaired by the lack of consistent provisions1. More-
over, taking into account that THMP are in most 
cases classiied as non-prescription medicinal prod-
ucts (OTC) and that there is a risk associated with 
possible interactions of herbal substances with other 
medicinal products, it is important to harmonise EU 
legislation on THMP.
7 Yet the EBA decision added that surgical methods such as the 
one described in the patent application is excluded from patent-
ability if it also requires professional medical expertise to be 
carried out.
8 G1/04, OJ EPO 2006 (Reason No 6.1).
* All views expressed in this paper are strictly personal and should 
not be understood or quoted as being made on behalf of the Eu-
ropean Medicines Agency.
** European Medicines Agency, London.
1 Please see recital 3 of the Directive 2004/24/EC.
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